---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-011315"
form_type: "8-K"
ticker: "CVKD"
cik: "0001937993"
company_name: "Cadrenal Therapeutics, Inc."
filed_at: "2025-02-07T23:59:59+00:00"
generated_at: "2026-05-27T01:04:32.190259+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Cadrenal appoints James J. Ferguson as CMO; Dr. Douglas Losordo departs

## Summary
- Dr. Ferguson, over 25 years cardiovascular experience, appointed Chief Medical Officer effective Feb 5, 2025.
- Annual base salary of $505,000; discretionary bonus up to 40% of base; option grant of 60,000 shares.
- Dr. Losordo separated amicably; severance includes 6-month salary continuation, bonus, and accelerated vesting.
- Dr. Ferguson to lead late-stage clinical development of tecarfarin including pivotal LVAD trial.
- Compensation includes option vesting: 25% on Mar 1, 2026, balance pro rata over 36 months.

## SEC filing metadata
- accession: 0001213900-25-011315
- form_type: 8-K
- ticker: CVKD
- cik: 0001937993
- company_name: Cadrenal Therapeutics, Inc.
- filed_at: 2025-02-07T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1937993/000121390025011315/0001213900-25-011315-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1937993/000121390025011315/ea0230166-8k_cadrenal.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-011315
- JSON: https://secwatch.observer/filing/0001213900-25-011315.json
- Plain text: https://secwatch.observer/filing/0001213900-25-011315.txt

## Key facts
- Executive change
  James J. Ferguson III was appointed as Chief Medical Officer at Cadrenal Therapeutics, Inc..
  - Action: appointed
  - Role: Chief Medical Officer
  source text: On February 4, 2025, Cadrenal Therapeutics, Inc. (the “Company”) entered into an employment agreement with James J. Ferguson III (the “Employment Agreement”), effective as of February 5, 2025 (the “Effective Date”), to employ Dr. Ferguson as the Company’s Chief Medical Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1937993/000121390025011315/0001213900-25-011315-index.htm
- Executive change
  Douglas Losordo was terminated as Chief Medical Officer at Cadrenal Therapeutics, Inc..
  - Action: terminated
  - Role: Chief Medical Officer
  source text: On February 4, 2025, the Company terminated its employment relationship with its Chief Medical Officer, Douglas Losordo, on a mutual amicable basis.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1937993/000121390025011315/0001213900-25-011315-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.